The growth of prostate cells depends upon the male hormone androgen. Therefore, androgen deprivation has remained the cornerstone of therapy for advanced prostate cancer for over half a century. However, novel immunomodulatory approaches including tumor vaccines are being developed to manage prostate cancer. A new modality using a tumor vaccine along with a cytotoxic agent was tested in a small group of patients with advanced, androgen-independent prostate cancer.
Go to Previous Page
Go to Next Page